Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Amphotericin b
Drug ID BADD_D00132
Description Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
Indications and Usage Used to treat potentially life threatening fungal infections.
Marketing Status approved; investigational
ATC Code A01AB04; A07AA07; G01AA03; J02AA01
DrugBank ID DB00681
KEGG ID D00203
MeSH ID D000666
PubChem ID 14956
TTD Drug ID D02DWM
NDC Product Code 65044-7183; 62756-233; 38779-0191; 51552-0304; 51927-1726; 62991-1173; 39822-1055; 55500-0001; 63622-0123; 63622-0124; 63622-0125; 0469-3051; 39635-0003; 45932-0008; 55150-365
UNII 7XU7A7DROE
Synonyms Amphotericin B | Amphotericin | Fungizone | Amphotericin B Cholesterol Dispersion | Amphotericin B Colloidal Dispersion | Amphocil
Chemical Information
Molecular Formula C47H73NO17
CAS Registry Number 1397-89-3; 30652-87-0
SMILES CC1C=CC=CC=CC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(CC(C(CCC(CC(CC(=O)OC(C(C1O)C)C)O)O)O) O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Injection site reaction12.07.03.015; 08.02.03.014--
Injury12.01.08.004--Not Available
Insomnia17.15.03.002; 19.02.01.002--
Instillation site pain12.07.01.008; 08.02.01.008--Not Available
Interstitial lung disease22.01.02.003; 10.02.01.0330.000094%Not Available
Jaundice23.03.03.030; 09.01.01.004; 01.06.04.004--Not Available
Leukocytosis01.02.01.002--
Leukopenia01.02.02.001--Not Available
Lip swelling23.04.01.007; 10.01.05.005; 07.05.04.0050.000094%Not Available
Liver disorder09.01.08.0010.000141%Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.004--Not Available
Lung disorder22.02.07.001--Not Available
Malaise08.01.01.003--
Melaena24.07.02.013; 07.12.02.004--Not Available
Meningitis cryptococcal17.06.04.001; 11.03.04.002--Not Available
Mental disability26.01.01.001--Not Available
Metabolic acidosis14.01.01.0030.000094%Not Available
Mouth haemorrhage24.07.02.014; 07.05.02.001--
Mouth ulceration07.05.06.004--Not Available
Mucosal inflammation08.01.06.0020.000094%Not Available
Muscle spasms15.05.03.004--
Musculoskeletal pain15.03.04.007--
Myalgia15.05.02.001--
Myocardial infarction24.04.04.009; 02.02.02.007--
Myocarditis02.04.03.0010.000094%
Nausea07.01.07.001--
Neck pain15.03.04.009--
Nephrocalcinosis20.04.01.001--Not Available
The 7th Page    First    Pre   7 8 9 10 11    Next   Last    Total 13 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene